Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
NCT01208896
Hemic and Lymphatic Diseases, Immune System Diseases
Angers, France
View Trial DetailsNCT Number: NCT00915096
The purpose of the study is to assess in a prospective series of patients with high tumor burden follicular lymphoma treated with R-CHOP, the predictive value of [18F]-FDG PET performed over (after 4 treatments), and at the end of the first-line treatment on progression-free survival at 2 years.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
CHU - Besançon, Besançon, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Time frame: 30 weeks
Time frame: Baseline
Time frame: 30 weeks
Time frame: Baseline
Time frame: Baseline
Time frame: 30 weeks
Lymphoma Study Association
Other
High Tumor Burden Follicular Lymphoma: Impact of [18F]-FDG Positron Emission Tomography (PET) in the Assessment of Treatment Response
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01208896
Hemic and Lymphatic Diseases, Immune System Diseases
Angers, France
View Trial DetailsNCT05784415
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT02996773
Actinomycetales Infections, Acute Lymphoblastic Leukemia
Tucson, Arizona, United States
View Trial DetailsNCT02278796
Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases
Linz, Austria
View Trial Details